NUGALVIQ

WIPO WIPO 2021

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark NUGALVIQ was filed as Word mark on 06/29/2021 at the World Intellectual Property Organization.

Trademark Details Last update: July 28, 2022

Trademark form Word mark
File reference 1611009
Countries Australia European Community United Kingdom Israel Japan Norway
Base trademark US No. 90430250, December 30, 2020
Application date June 29, 2021
Expiration date June 29, 2031

Trademark owner

545 Fifth Avenue, Suite 1400
New York NY 10017
US

Trademark representatives

555 13th Street NW Washington DC 20004 US

goods and services

05 Pharmaceutical preparations for treatment of rare orphan diseases; pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; pharmaceutical preparations for inhibiting aldose reductase; pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) and PMM2-congential disorder of glycosylation (PMM2-CDG)

Trademark history

Date Document number Area Entry
July 20, 2022 2022/29 Gaz NO Rejection
June 23, 2022 2022/25 Gaz JP Rejection
May 2, 2022 2022/19 Gaz IL Rejection
January 19, 2022 2022/3 Gaz EM Rejection
January 5, 2022 2022/1 Gaz GB Rejection
November 23, 2021 2021/47 Gaz AU Rejection
June 29, 2021 2021/33 Gaz US Registration

ID: 141611009